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I hypothesize that human chronic autoimmune diseases are based on infection of 
autoreactive B lymphocytes by Epstein–Barr virus (EBV), in the following proposed 
scenario. During primary infection, autoreactive B cells are infected by EBV, 
proliferate and become latently infected memory B cells, which are resistant to the 
apoptosis that occurs during normal B-cell homeostasis because they express virus-
encoded anti-apoptotic molecules. Genetic susceptibility to the effects of B-cell 
infection by EBV leads to an increased number of latently infected autoreactive 
memory B cells, which lodge in organs where their target antigen is expressed, and 
act there as antigen-presenting cells. When CD4+ T cells that recognize antigens 
within the target organ are activated in lymphoid organs by cross-reactivity with 
infectious agents, they migrate to the target organ but fail to undergo activation-
induced apoptosis because they receive a co-stimulatory survival signal from the 
infected B cells. The autoreactive T cells proliferate and produce cytokines, which 
recruit other inflammatory cells, with resultant target organ damage and chronic 
autoimmune disease. 
 
Epstein–Barr virus (EBV) has been suspected of involvement in the aetiology of 
various human chronic autoimmune diseases since the finding of elevated levels of 
antibodies to the virus in systemic lupus erythematosus (SLE) in 1971 1. There is now 
a large body of evidence implicating the virus in several different autoimmune 
diseases, including SLE 1 2 3, multiple sclerosis (MS) 4 5 6 7 8, Sjögren's syndrome 9 10 
11, rheumatoid arthritis 12, autoimmune thyroiditis 13, autoimmune hepatitis 14, 
cryptogenic fibrosing alveolitis 15 and pure red cell aplasia 16 17. Published hypotheses 
generally focus on individual autoimmune diseases and are based primarily on cross-
reactivity between EBV and self-antigens or on EBV-targeted immune-mediated 
organ damage. Here, I propose a novel hypothesis that is based primarily on the 
unique ability of EBV to infect, activate and latently persist in B lymphocytes, 
including autoreactive B cells, and that incorporates the known association of 
different autoimmune diseases in individuals and among family members. The 
advantage of this hypothesis over previous hypotheses for a unique role of EBV in 
chronic autoimmune disease is that it is based on what is unique about the relationship 
between EBV and the immune system, namely its ability to immortalize B cells, 
rather than what is common to all viruses, which is the potential for molecular 
mimicry and cross-reactivity between viral and self-antigens. The hypothesis also 
incorporates a role for CD4+ T-cell cross-reactivity between viral (including EBV) 
antigens and self-antigens to explain why people with different MHC class II genes 
develop chronic autoimmune disease in different target organs following EBV 
infection of B cells. My hypothesis differs from that of Haahr and Munch 18, in that it 
provides a rationale for the importance of B-cell infection by EBV, it implicates 
genetic susceptibility and all chronic autoimmune diseases (not just MS) and it does 
not involve a retrovirus.  
1. Universally high prevalence of EBV seropositivity in MS and SLE 
Elevated levels of antibodies to various viruses are present in people with different 
chronic autoimmune diseases. What is unique and striking about the serology for 
EBV is that it is almost universally (>99%) positive in those autoimmune diseases in 
which it has been thoroughly studied, namely SLE 3 and MS 7, compared to a 
positivity rate of 90% in the general adult population. The positivity rate of 99% in 
SLE is maintained even in young subjects where the general rate is only 70% 3. These 
findings do not apply to other herpes viruses. Further studies are required to determine 
whether other human chronic autoimmune diseases are also associated with such a 
high seropositivity rate for EBV.  
The fact that virtually all individuals with SLE or MS are EBV-seropositive suggests 
that prior infection with EBV is essential for the development of these autoimmune 
diseases. However, infection itself is clearly not sufficient for disease development. 
The timing and severity of primary infection also have a role. Chronic autoimmune 
diseases are uncommon in the developing world where primary infection with EBV 
occurs much earlier and probably with a lower dose of virus than in the developed 
world 19. Furthermore, a definite clinical history of infectious mononucleosis, which 
indicates primary infection with a high frequency of infected B cells 19, further 
increases the risk of MS in EBV-seropositive subjects (eightfold, if infection occurs 
before the age of 18 years) 6. Recently, Levin et al. 8, in a study of blood samples from 
US military personnel collected before the onset of MS, have shown that the presence 
of high titres of antibodies to EBV increases the risk 34-fold for developing MS. 
However, differences in environmental exposure to EBV are not sufficient to explain 
why only a minority of infected individuals develops autoimmune disease. There must 
also be another determinant. Is genetic susceptibility to the effects of B-cell infection 
by EBV the determinant?  
2. Genetic susceptibility to ‘autoimmunity-in-general’ in individuals with 
different chronic autoimmune diseases 
Genetic factors clearly contribute to the development of chronic autoimmune 
diseases. MHC class II genes account for part of the genetic susceptibility but other 
genes must also be involved. The fact that individual autoimmune diseases, such as 
MS, are associated with other autoimmune diseases in affected individuals and family 
members 20 21, suggests a genetic predisposition to ‘autoimmunity-in-general’. Indeed, 
studies on autoimmune family pedigrees have led to the proposal that autoimmunity is 
an autosomal dominant trait with penetrance (disease expression) in ~92% of females 
and 49% of males carrying the abnormal gene 22. Is the autoimmune trait a result of a 
genetic susceptibility to the effects of B-cell infection by EBV? There are several 
possible general mechanisms for such genetic susceptibility, namely: increased uptake 
of virus by B cells (e.g. increased expression of CD21, the receptor for the virus), 
decreased elimination of virus-infected B cells by EBV-specific cytotoxic CD8+ T 
cells (e.g. due to decreased processing of EBV antigens or decreased expression of 
MHC class I molecules), and indirect mechanisms superimposed on B-cell infection 
(e.g. a genetic defect in the immunoregulation of autoreactive B cells). 
3. Infection of B cells of normal individuals with EBV results in the 
production of monoclonal autoantibodies 
When EBV infects resting B cells in vitro, it drives them into activation and 
proliferation independently of T-cell help. Infection of B cells from normal 
individuals in vitro results in the production of monoclonal autoantibodies reacting 
with antigens in multiple organs 23. This accounts for the transient appearance of 
autoantibodies during the course of infectious mononucleosis 19. Usually, the 
proliferating infected B cells are eventually eliminated by EBV-specific cytotoxic 
CD8+ T cells (Figure 1) but latently infected non-proliferating memory B cells persist 
in the individual for life 24. Antigen-driven differentiation of latently infected memory 
B cells into plasma cells might trigger entry into the lytic cycle with the production of 
infectious virus 24. 
 Figure 1. Role of B cells latently infected by EBV in chronic autoimmune disease. During primary 
infection with EBV, EBV infects B cells, including autoreactive B cells, in the tonsil (Step 1), causing 
them to undergo T-cell-independent clonal expansion (Step 2). The activated infected B cells circulate 
in the blood (Step 3). The number of infected B cells is normally controlled by EBV-specific cytotoxic 
CD8+ T cells, which kill the infected B cells (Step 4) but not if there is a genetically determined defect 
in this mechanism, for example, decreased MHC class I expression on B cells. Surviving EBV-infected 
autoreactive B cells lodge and persist in organs containing the self-antigen they recognize (Step 5). 
When CD4+ T cells are activated in peripheral lymphoid organs following viral (including EBV) 
infections, they circulate in the peripheral blood, traffic through non-lymphoid organs and lodge in the 
target organ containing the self-antigen with which they cross-react (Step 6 or 8). Normally, these T 
cells are eliminated in the target organ by activation-induced T-cell apoptosis following interaction 
with class II MHC-expressing non-professional APCs (Step 8). However, if instead they interact with 
EBV-infected autoreactive B cells lodged in the organ, they receive a co-stimulatory survival signal 
that inhibits activation-induced T-cell apoptosis (Step 6). The CD4+ T cells survive, activate the B cells 
to produce Ab, which reacts with the target organ, and act as effector T cells leading to autoimmune 
target organ damage (Step 7). Abbreviations: Ab, antibody; APCs, antigen-presenting cells; BCR, B-
cell receptor; EBV, Epstein–Barr virus; ep-MHC, EBV peptide complexed to MHC class I; IFN- , 
interferon- ; IL-2, interleukin-2; TCR, T-cell receptor; TNF- , tumour necrosis factor- ; tp-MHC, 
target antigen peptide complexed to MHC class II. B7 represents co-stimulatory molecules and CD28 
represents their receptors on the T cell.  
4. Defective T-cell control of EBV-infected B cells in different chronic 
autoimmune diseases 
Patients with rheumatoid arthritis (RA) have an abnormally increased frequency of 
circulating EBV-infected B cells 12. This is not due to an increased uptake of virus by 
B cells but could be explained by the defective control of infected B cells by EBV-
specific T cells  12. A similar defect is also present in MS 5, SLE 2 and Sjögren's 
syndrome 9 10. In SLE, T cells from normal EBV-seropositive subjects can control the 
numbers of infected B cells from SLE patients but T cells from patients cannot control 
infected B cells from normal subjects or patients 2; this indicates impaired viral 
control by T cells. In Sjögren's syndrome, the defective viral control is due to 
decreased EBV-specific T-cell cytotoxicity  9. However, all these studies on T-cell 
control of EBV in chronic autoimmune disease were performed before the 
identification of CD8+ T-cell EBV epitopes and have not been subsequently studied 
in the light of this knowledge. Nevertheless, these early studies raise the possibility 
that a genetically determined defect in the generation of EBV-specific cytotoxic 
CD8+ T cells might lead to the impaired elimination of EBV-infected B cells in 
chronic autoimmune disease.  
One possible genetic mechanism for decreased EBV-specific cytotoxic CD8+ T cells 
is deficient MHC class I expression on B cells, which has been reported to occur in 
chronic autoimmune diseases, including insulin-dependent diabetes mellitus, 
Hashimoto's thyroiditis, Graves' disease, SLE, RA, Sjögren's syndrome and MS 25 26, 
although it remains unclear whether the reported decrease is sufficient to account for 
decreased T-cell cytotoxicity. Alternatively, it could be argued that the above T- and 
B-cell changes in chronic autoimmune disease might be secondary to immune 
dysfunction associated with autoimmune disease, and that a genetic defect in the 
immunoregulation of B cells could enable the persistence and proliferation of memory 
autoreactive B cells infected with EBV.  
5. Do EBV-infected autoreactive B cells persist in the target organs and 
promote autoimmune disease? 
I propose that, following primary EBV infection in individuals with a genetic 
predisposition to autoimmunity, virus-infected activated autoreactive B cells circulate 
in the blood and accumulate in organs containing the target antigen. Activated 
antigen-specific B cells can traffic across even the intact blood–brain barrier and can 
lodge in the brain if the antigen is present 27. Thus, it appears that activated B cells 
traffic in the same way as activated T cells, which preferentially migrate from the 
blood into non-lymphoid organs, as opposed to resting T cells, which exit through 
lymph node high-endothelial venules 28. The EBV-infected autoreactive B cells might 
persist in the target organ independently of T-cell help because latently-infected B 
cells express viral latent membrane proteins that protect them from the apoptosis that 
occurs during normal B-cell homeostasis 24 and in the target organ in self-limited 
autoimmune disease 29. Latently infected B cells could be the source of the 
monoclonally expanded B cells in the salivary glands in Sjögren's syndrome 30, the 
thyroid gland in autoimmune thyroiditis 31 and the brain in MS 32. These B cells could 
act as antigen-presenting cells (APCs), which present their cognate antigen and other 
physically linked self-antigens to activated autoreactive T cells trafficking through the 
target organ ( Figure 1).  
Healthy subjects experience surges of circulating autoreactive T cells, presumably 
activated by cross-reacting infectious agents 33. I have proposed that these T cells 
would normally be eliminated in the target organ by activation-induced apoptosis ( 
Figure 1) but could survive if they received co-stimulatory signals from professional 
APCs, such as B cells 34 35. Autoreactive B cells latently infected by EBV might 
provide this co-stimulatory survival signal to T cells in the target organ. The 
autoreactive T cells could then proliferate and produce cytokines, which recruit and 
activate macrophages and other B and T cells, with resultant target organ damage. In 
turn, target organ damage would lead to the release of autoantigens and further T-cell 
and B-cell activation, with spreading of the immune response to other antigens and 
perpetuation of the immune attack. Latently infected B cells might also produce B-
cell-attracting chemokine-1, enabling the development of germinal centres in the 
target organ 36. This model would not depend on latently infected B cells becoming 
lytically infected and releasing infectious virus in the target organ, but if this occurred 
after differentiation into plasma cells, it could lead to infection and proliferation of 
other autoreactive B cells and to recruitment of T cells specific for lytic-cycle viral 
antigens with further immune attack. The presence of EBV-infected B cells in the 
target organ could also result in the development of B-cell lymphoma, which has been 
reported to occur within the salivary glands in Sjögren's syndrome 37, within the 
thyroid gland in autoimmune thyroiditis 38 and within the central nervous system in 
MS 39. 
6. Role of MHC 
Specific alleles of MHC class II have an important role in determining the risk of 
developing particular autoimmune diseases. The mechanism for this is unclear but one 
possibility is that these specific alleles determine which self-antigens (and therefore 
which organs) are recognized by cross-reacting CD4+ T cells that have been activated 
by foreign antigens. This situation might be analogous to that proposed for the 
shaping of the CD8+ T-cell repertoire against alloantigens by MHC class I-restricted 
antiviral T-cell responses 40. Acute viral infections, including EBV, can lead to 
dramatic clonal expansion of T cells 24 40, which could cross-react with other antigens. 
For example, CD8+ T-cell clones specific for a HLA-B8-restricted EBV epitope 
cross-react with several common HLA-B alleles as alloantigens 40; EBV-specific T 
cells cross-react with self-HLA alleles in oligoarticular juvenile idiopathic arthritis 41; 
and a CD4+ T-cell clone reacts with both a DRB5*0101-restricted EBV peptide and a 
DRB1*1501-restricted myelin basic protein peptide in MS 42. During acute EBV and 
other viral infections, MHC class II genes will determine the fine specificities of the 
virus-reactive CD4+ T-cell populations and thus determine which self-antigens are 
targeted by cross-reacting virus-specific CD4+ T cells, and therefore in which organs 
autoimmune disease develops after interaction between the circulating activated T 
cells and resident autoreactive B cells. Thus, CD4+ T-cell cross-reactivity between 
viral antigens and self-antigens could explain why people with different class II MHC 
genes develop chronic autoimmune disease in different target organs following EBV 
infection of B cells. This model does not depend on recognition of B-cell EBV 
antigens by EBV-specific T cells in the target organ but if this occurred it would 
contribute to the immune attack. 
7. Testing the hypothesis 
To test the hypothesis, first, monoclonal B-cell populations could be isolated from 
target organs (e.g. cerebrospinal fluid, thyroid gland, synovium) and examined to 
determine whether they express EBV-encoded small nuclear RNAs (EBERs), virus-
encoded anti-apoptotic latent membrane proteins, co-stimulatory molecules and B-
cell-attracting chemokine-1, and also to determine whether they are autoreactive 
against the organ from which they have been isolated. These studies will be 
technically demanding, will require the use of appropriate controls and will need care 
in analysis and interpretation. For example, in a study using a highly sensitive in situ 
hybridization technique to detect EBERs in synovial membrane biopsy samples of 
patients with RA, it was concluded that there was a lack of evidence for involvement 
of EBV 43. Yet, the study actually found EBERs in seven (19%) of 37 patients with 
RA and in zero of 51 patients with other joint diseases; cells expressing EBERs were 
B cells and plasma cells. These results could also be interpreted as supporting a role 
for EBV infection of B cells in the pathogenesis of RA if the negative results in the 
other patients with RA were due to the limitations imposed by sampling.  
Second, it could be determined whether autologous EBV-specific cytotoxic CD8+ T 
cells from the peripheral blood fail to kill EBV-infected autoreactive B cells from the 
target organ, for example, because of defective MHC class I expression by B cells. 
Third, it could be analyzed whether EBV-specific CD4+ T-cell lines react with self-
antigens from the target organ presented by autologous APCs. Unlike the other tests 
proposed here, this test does not depend on B-cell infection by EBV but rather is a test 
for cross-reactivity between EBV and self-antigens. Fourth, monozygotic twins 
discordant for autoimmune disease should be tested for differences in frequencies of 
EBV-infected B cells, T-cell cytotoxicity against infected B cells and MHC class I 
expression. Finally and most importantly, if the hypothesis is correct, control of EBV-
infected B cells should inhibit the progression of chronic autoimmune diseases. Such 
control might be achieved by: general B-cell depletion (e.g. by rituximab); 
transferring EBV-specific cytotoxic CD8+ T cells; antiviral agents or agents that 
interfere with the anti-apoptotic effects of viral latent membrane proteins.  
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